Trial Profile

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Dacarbazine (Primary) ; Doxorubicin (Primary) ; Pembrolizumab (Primary)
Indications Hodgkin's disease
Focus Adverse reactions; Therapeutic Use

Most Recent Events

10 Oct 2025 Planned primary completion date changed from 30 Oct 2025 to 30 Oct 2027.
10 Oct 2025 Status changed from recruiting to active, no longer recruiting.
14 May 2025 Planned number of patients changed from 50 to 25.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com